<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04896658</url>
  </required_header>
  <id_info>
    <org_study_id>2060GCCC</org_study_id>
    <nct_id>NCT04896658</nct_id>
  </id_info>
  <brief_title>Belantamab Mafodotin, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma</brief_title>
  <official_title>Belantamab Mafodotin, Cyclophosphamide and Dexamethasone in Relapsed/Refractory Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Maryland, Baltimore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Maryland, Baltimore</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the efficacy and safety of Belantamab Mafodotin, cyclophosphamide, and dexamethasone&#xD;
      in patients with Relapsed/Refractory Multiple Myeloma&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase I/II, open-label study to evaluate the efficacy and safety of Belantamab&#xD;
      Mafodotin, cyclophosphamide, and dexamethasone.&#xD;
&#xD;
      In Phase I, the subjects will be assigned into two arms and there are two dose levels for&#xD;
      Belantamab Mafodotin and there are two dose levels of cyclophosphamide in each arm.&#xD;
&#xD;
      In Phase II, once tolerability of the highest planned dose is established, the patients will&#xD;
      be assessed for response rate. The arm with acceptable toxicity and best response will be&#xD;
      further assessed in the expansion cohort.&#xD;
&#xD;
      Belantamab mafodotin was approved by the U.S. Food and Drug Administration (FDA) on Aug 5,&#xD;
      2020, for treating patients with relapsed/refractory multiple myeloma. Cyclophosphamide and&#xD;
      dexamethasone are both approved by the FDA. But the combinations with these three drugs to&#xD;
      treat people with relapsed/refractory multiple myeloma has not been approved by the FDA.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2022</start_date>
  <completion_date type="Anticipated">March 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Phase I&#xD;
Arm A (cycles repeated every 3 weeks)&#xD;
Dose level 1: The subject will take 1.9 mg/kg of Belantamab Mafodotin, 300 mg of Cyclophosphamide, and 40 mg of Dexamethasone on day 1 of each 3 weeks cycles.&#xD;
Dose level 2: The subject will take 1.9 mg/kg of Belantamab Mafodotin, 500 mg of Cyclophosphamide, and 40 mg of Dexamethasone on day 1 of each 3 weeks cycles.&#xD;
Arm B (cycles repeated every 6 weeks)&#xD;
Dose level 1: The subject will take 2.5 mg/kg of Belantamab Mafodotin, 300 mg of Cyclophosphamide, and 40 mg of Dexamethasone on day 1 of each 6 weeks cycles.&#xD;
Dose level 2: The subject will take 2.5 mg/kg of Belantamab Mafodotin, 500 mg of Cyclophosphamide, and 40 mg of Dexamethasone on day 1 of each 6 weeks cycles.&#xD;
Phase II&#xD;
Once tolerability of the highest planned dose is established, patients will be assessed for response rate. The arm with acceptable toxicity and best response will be further assessed in the expansion cohort.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall incidence and severity of AEs in Dose Escalation</measure>
    <time_frame>Up to 6 weeks</time_frame>
    <description>Overall incidence and severity of Adverse Events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Response rate in Expansion Cohort</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>percentage of patients with confirmed partial response or better and time to disease progression in responding patients.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
    <time_frame>From date of randomization until the date of death from any cause, assessed up to 100 months</time_frame>
    <description>Time till the disease progresses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>From date of randomization until the date of death from any cause, assessed up to 100 months</time_frame>
    <description>time for study drugs to control the disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>From date of randomization until the date of death from any cause, assessed up to 100 months</time_frame>
    <description>total life expectancy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cytokine Profile Data</measure>
    <time_frame>At the start of Cycle 2, Day 1 (a cycle is 28 days)</time_frame>
    <description>The following Human Essential Immune Response Pane will be assessed:IL-4, IL-2, CXCL10 (IP-10), IL-1β, TNF-α, CCL2 (MCP-1), IL-17A, IL-6, IL-10, IFN-γ, IL-12p70, TGF-β1 (Free Active), CXCL8 (IL-8).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Relapsed/Refractory Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose level 1: The subject will take 1.9 mg/kg of Belantamab Mafodotin, 300 mg of Cyclophosphamide, and 40 mg of Dexamethasone on day 1 of each 3 weeks cycles.&#xD;
Dose level 2: The subject will take 1.9 mg/kg of Belantamab Mafodotin, 500 mg of Cyclophosphamide, and 40 mg of Dexamethasone on day 1 each 3 weeks cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose level 1: The subject will take 2.5 mg/kg of Belantamab Mafodotin, 300 mg of Cyclophosphamide, and 40 mg of Dexamethasone on day 1 of each 6 weeks cycles.&#xD;
Dose level 2: The subject will take 2.5 mg/kg of Belantamab Mafodotin, 500 mg of Cyclophosphamide, and 40 mg of Dexamethasone on day 1 each 6 weeks cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Belantamab Mafodotin, Cyclophosphamide and Dexamethasone</intervention_name>
    <description>Study drug</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically confirmed diagnosis of Refractory MM; failed at least 3 prior lines of&#xD;
             anti-myeloma treatments, including an anti-CD38 antibody (e.g., daratumumab) alone or&#xD;
             in combination, and is refractory to an IMiD (i.e., lenalidomide or pomalidomide), and&#xD;
             to a proteasome inhibitor (e.g., bortezomib, ixazomib or carfilzomib). (Refractory&#xD;
             myeloma is defined as disease that is nonresponsive while on primary or salvage&#xD;
             therapy or progresses within 60 days of last therapy. Nonresponsive disease is defined&#xD;
             as either failure to achieve at least minimal response or development of progressive&#xD;
             disease (PD) while on therapy).&#xD;
&#xD;
          2. Has measurable disease with at least one of the following:&#xD;
&#xD;
               1. Serum M-protein ≥0.5 g/dL (≥ 5 g/L)&#xD;
&#xD;
               2. Urine M-protein ≥ 200 mg/24h&#xD;
&#xD;
               3. Serum FLC assay: Involved FLC level ≥10 mg/dL and an abnormal ratio (&lt;0.26 or&#xD;
                  &gt;1.65)&#xD;
&#xD;
          3. Provide signed written informed consent.&#xD;
&#xD;
          4. 18 years or older (at the time consent is obtained).&#xD;
&#xD;
          5. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.&#xD;
&#xD;
          6. Participants with a history of autologous stem cell transplant or Prior BCMA targeted&#xD;
             therapy (e.g. CAR-T cells, BiTes) can enroll on the study provided that:&#xD;
&#xD;
               1. Therapy was &gt;100 days prior to study enrolment.&#xD;
&#xD;
               2. No active infection(s).&#xD;
&#xD;
          7. Adequate organ system function (as defined by inclusion criteria #7).&#xD;
&#xD;
          8. Female and Male patients: Contraceptive use by men or women should be consistent with&#xD;
             local regulations regarding the methods of contraception for those participating in&#xD;
             clinical studies.&#xD;
&#xD;
          9. Prior treatment-related toxicities must be ≤ Grade 1 except peripheral neuropathy&#xD;
             (Grade-2).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Systemic anti-myeloma therapy within ≤14 days or 5 half-lives, whichever is shorter,&#xD;
             or plasmapheresis within 7 days prior to treatment.&#xD;
&#xD;
          2. Systemic treatment with high dose steroids (equivalent to ≥ 60 mg prednisone daily for&#xD;
             ≥4 days) within the past 14 days.&#xD;
&#xD;
          3. Symptomatic amyloidosis, active CNS disease, active plasma cell leukemia at the time&#xD;
             of screening.&#xD;
&#xD;
          4. Prior allogeneic stem cell transplant (SCT). NOTE - Participants who have undergone&#xD;
             syngeneic transplant may be allowed if no history of GvHD.&#xD;
&#xD;
          5. Current corneal epithelial disease except mild punctate keratopathy.&#xD;
&#xD;
          6. Evidence of active bleeding.&#xD;
&#xD;
          7. Any major surgery within the last four weeks.&#xD;
&#xD;
          8. Presence of active renal condition (infection, dialysis); isolated proteinuria from MM&#xD;
             is allowed provided participants fulfil the adequate organ system function criteria&#xD;
             (as defined by inclusion criteria #7).&#xD;
&#xD;
          9. Any serious and/or unstable pre-existing medical, psychiatric disorder or lab&#xD;
             abnormalities that affect patients' safety, obtaining informed consent or compliance&#xD;
             with study procedures.&#xD;
&#xD;
         10. Current unstable liver disease defined by the presence of ascites, encephalopathy,&#xD;
             coagulopathy, hypoalbuminemia, esophageal or gastric varices, persistent jaundice, or&#xD;
             cirrhosis. NOTE: Stable non-cirrhotic chronic liver disease (including Gilbert's&#xD;
             syndrome or asymptomatic gallstones) is acceptable if participant otherwise meets&#xD;
             entry criteria.&#xD;
&#xD;
         11. Other malignancies except for malignancy from which the patients have been&#xD;
             disease-free &gt; 2 years.&#xD;
&#xD;
         12. Evidence of cardiovascular disease including any of the following:&#xD;
&#xD;
               1. Evidence of current clinically significant untreated arrhythmias, including&#xD;
                  clinically significant ECG abnormalities including second degree (Mobitz Type II)&#xD;
                  or third degree atrioventricular (AV) block.&#xD;
&#xD;
               2. History of myocardial infarction, acute coronary syndromes (including unstable&#xD;
                  angina), coronary angioplasty, or stenting or bypass grafting within 3 months of&#xD;
                  Screening.&#xD;
&#xD;
               3. Class III or IV heart failure as defined by the New York Heart Association&#xD;
                  functional classification system.&#xD;
&#xD;
               4. Uncontrolled hypertension.&#xD;
&#xD;
         13. Known immediate or delayed hypersensitivity reaction or idiosyncratic reaction to&#xD;
             drugs chemically related to belantamab mafodotin, daratumumab, bortezomib, boron or&#xD;
             mannitol or any other components of the study treatment.&#xD;
&#xD;
         14. Active infection requiring treatment.&#xD;
&#xD;
         15. Known HIV infection.&#xD;
&#xD;
         16. Presence of hepatitis B surface antigen (HbsAg), or hepatitis B core antibody (HbcAb),&#xD;
             at screening or within 3 months prior to first dose of study treatment. Note: presence&#xD;
             of Hep B surface antibody (HBsAb) indicating previous vaccination will not exclude a&#xD;
             participant.&#xD;
&#xD;
         17. Positive hepatitis C antibody test result or positive hepatitis C RNA test result at&#xD;
             screening or within 3 months prior to first dose of study treatment.&#xD;
&#xD;
             NOTE: Participants with positive hepatitis C antibody due to prior resolved disease&#xD;
             can be enrolled, only if a confirmatory negative Hepatitis C RNA test is obtained.&#xD;
             Hepatitis RNA testing is optional and participants with negative hepatitis C antibody&#xD;
             test are not required to also undergo hepatitis C RNA testing.&#xD;
&#xD;
         18. Symptomatic amyloidosis, active POEMS syndrome (polyneuropathy, organomegaly,&#xD;
             endocrinopathy, monoclonal plasma proliferative disorder, skin changes) or active&#xD;
             plasma cell leukemia at the time of screening.&#xD;
&#xD;
         19. Pregnant or lactating female.&#xD;
&#xD;
         20. Concomitant administration of strong P-glycoprotein inhibitors and inhibitors of OATP&#xD;
             will be avoided.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ashraf Badros, MB; ChB</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Maryland, Baltimore</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ashraf Badros, MB; ChB</last_name>
    <phone>410) 328-1230</phone>
    <email>abadros@UMM.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sunita Sunita</last_name>
    <phone>410-328-8199</phone>
    <email>sphilip1@umm.edu</email>
  </overall_contact_backup>
  <reference>
    <citation>Alley SC, Zhang X, Okeley NM, Anderson M, Law CL, Senter PD, Benjamin DR. The pharmacologic basis for antibody-auristatin conjugate activity. J Pharmacol Exp Ther. 2009 Sep;330(3):932-8. doi: 10.1124/jpet.109.155549. Epub 2009 Jun 4.</citation>
    <PMID>19498104</PMID>
  </reference>
  <reference>
    <citation>Chari A, Vogl DT, Gavriatopoulou M, Nooka AK, Yee AJ, Huff CA, Moreau P, Dingli D, Cole C, Lonial S, Dimopoulos M, Stewart AK, Richter J, Vij R, Tuchman S, Raab MS, Weisel KC, Delforge M, Cornell RF, Kaminetzky D, Hoffman JE, Costa LJ, Parker TL, Levy M, Schreder M, Meuleman N, Frenzel L, Mohty M, Choquet S, Schiller G, Comenzo RL, Engelhardt M, Illmer T, Vlummens P, Doyen C, Facon T, Karlin L, Perrot A, Podar K, Kauffman MG, Shacham S, Li L, Tang S, Picklesimer C, Saint-Martin JR, Crochiere M, Chang H, Parekh S, Landesman Y, Shah J, Richardson PG, Jagannath S. Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma. N Engl J Med. 2019 Aug 22;381(8):727-738. doi: 10.1056/NEJMoa1903455.</citation>
    <PMID>31433920</PMID>
  </reference>
  <reference>
    <citation>Dougherty BE, Nichols JJ, Nichols KK. Rasch analysis of the Ocular Surface Disease Index (OSDI). Invest Ophthalmol Vis Sci. 2011 Nov 7;52(12):8630-5. doi: 10.1167/iovs.11-8027.</citation>
    <PMID>21948646</PMID>
  </reference>
  <reference>
    <citation>Gandhi UH, Cornell RF, Lakshman A, Gahvari ZJ, McGehee E, Jagosky MH, Gupta R, Varnado W, Fiala MA, Chhabra S, Malek E, Mansour J, Paul B, Barnstead A, Kodali S, Neppalli A, Liedtke M, Narayana S, Godby KN, Kang Y, Kansagra A, Umyarova E, Scott EC, Hari P, Vij R, Usmani SZ, Callander NS, Kumar SK, Costa LJ. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia. 2019 Sep;33(9):2266-2275. doi: 10.1038/s41375-019-0435-7. Epub 2019 Mar 11.</citation>
    <PMID>30858549</PMID>
  </reference>
  <reference>
    <citation>Heylmann D, Bauer M, Becker H, van Gool S, Bacher N, Steinbrink K, Kaina B. Human CD4+CD25+ regulatory T cells are sensitive to low dose cyclophosphamide: implications for the immune response. PLoS One. 2013 Dec 23;8(12):e83384. doi: 10.1371/journal.pone.0083384. eCollection 2013.</citation>
    <PMID>24376696</PMID>
  </reference>
  <reference>
    <citation>Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, Munshi N, Lonial S, Bladé J, Mateos MV, Dimopoulos M, Kastritis E, Boccadoro M, Orlowski R, Goldschmidt H, Spencer A, Hou J, Chng WJ, Usmani SZ, Zamagni E, Shimizu K, Jagannath S, Johnsen HE, Terpos E, Reiman A, Kyle RA, Sonneveld P, Richardson PG, McCarthy P, Ludwig H, Chen W, Cavo M, Harousseau JL, Lentzsch S, Hillengass J, Palumbo A, Orfao A, Rajkumar SV, Miguel JS, Avet-Loiseau H. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016 Aug;17(8):e328-e346. doi: 10.1016/S1470-2045(16)30206-6. Review.</citation>
    <PMID>27511158</PMID>
  </reference>
  <reference>
    <citation>Kumar SK, Lee JH, Lahuerta JJ, Morgan G, Richardson PG, Crowley J, Haessler J, Feather J, Hoering A, Moreau P, LeLeu X, Hulin C, Klein SK, Sonneveld P, Siegel D, Bladé J, Goldschmidt H, Jagannath S, Miguel JS, Orlowski R, Palumbo A, Sezer O, Rajkumar SV, Durie BG; International Myeloma Working Group. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia. 2012 Jan;26(1):149-57. doi: 10.1038/leu.2011.196. Epub 2011 Jul 29. Erratum in: Leukemia. 2012 May;26(5):1153. Nari, Hareth [corrected to Nahi, Hareth].</citation>
    <PMID>21799510</PMID>
  </reference>
  <reference>
    <citation>Laurent SA, Hoffmann FS, Kuhn PH, Cheng Q, Chu Y, Schmidt-Supprian M, Hauck SM, Schuh E, Krumbholz M, Rübsamen H, Wanngren J, Khademi M, Olsson T, Alexander T, Hiepe F, Pfister HW, Weber F, Jenne D, Wekerle H, Hohlfeld R, Lichtenthaler SF, Meinl E. γ-Secretase directly sheds the survival receptor BCMA from plasma cells. Nat Commun. 2015 Jun 11;6:7333. doi: 10.1038/ncomms8333.</citation>
    <PMID>26065893</PMID>
  </reference>
  <reference>
    <citation>Lonial S, Lee HC, Badros A, Trudel S, Nooka AK, Chari A, Abdallah AO, Callander N, Lendvai N, Sborov D, Suvannasankha A, Weisel K, Karlin L, Libby E, Arnulf B, Facon T, Hulin C, Kortüm KM, Rodríguez-Otero P, Usmani SZ, Hari P, Baz R, Quach H, Moreau P, Voorhees PM, Gupta I, Hoos A, Zhi E, Baron J, Piontek T, Lewis E, Jewell RC, Dettman EJ, Popat R, Esposti SD, Opalinska J, Richardson P, Cohen AD. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 2020 Feb;21(2):207-221. doi: 10.1016/S1470-2045(19)30788-0. Epub 2019 Dec 16.</citation>
    <PMID>31859245</PMID>
  </reference>
  <reference>
    <citation>Macsai M, Nariani A, Gan H, Lassman A, Merrell R, Gomez E, et al. Corneal Toxicity of ABT-414 in Glioblastoma (GBM): Clinical Manifestations, Ophthalmological Findings and Management. Investigative Ophthalmology &amp; Visual Science. 2016 Sep 26;57(12):269-269.</citation>
  </reference>
  <reference>
    <citation>Xie J, He Y. Ontology-Based Vaccine Adverse Event Representation and Analysis. Adv Exp Med Biol. 2017;1028:89-103. doi: 10.1007/978-981-10-6041-0_6. Review.</citation>
    <PMID>29058218</PMID>
  </reference>
  <reference>
    <citation>Novak AJ, Darce JR, Arendt BK, Harder B, Henderson K, Kindsvogel W, Gross JA, Greipp PR, Jelinek DF. Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival. Blood. 2004 Jan 15;103(2):689-94. Epub 2003 Sep 25.</citation>
    <PMID>14512299</PMID>
  </reference>
  <reference>
    <citation>Pirogova OV, Moiseev IS, Surkova EA, Lapin SV, Bondarenko SN, Kulagin AD, Afanasyev BV. Profiles of pro-inflammatory cytokines in allogenic stem cell transplantation with post-transplant cyclophosphamide. Cytokine. 2017 Nov;99:148-153. doi: 10.1016/j.cyto.2017.08.016. Epub 2017 Sep 9.</citation>
    <PMID>28898706</PMID>
  </reference>
  <reference>
    <citation>Roghanian A, Hu G, Fraser C, Singh M, Foxall RB, Meyer MJ, Lees E, Huet H, Glennie MJ, Beers SA, Lim SH, Ashton-Key M, Thirdborough SM, Cragg MS, Chen J. Cyclophosphamide Enhances Cancer Antibody Immunotherapy in the Resistant Bone Marrow Niche by Modulating Macrophage FcγR Expression. Cancer Immunol Res. 2019 Nov;7(11):1876-1890. doi: 10.1158/2326-6066.CIR-18-0835. Epub 2019 Aug 26.</citation>
    <PMID>31451483</PMID>
  </reference>
  <reference>
    <citation>Sanchez E, Li M, Kitto A, Li J, Wang CS, Kirk DT, Yellin O, Nichols CM, Dreyer MP, Ahles CP, Robinson A, Madden E, Waterman GN, Swift RA, Bonavida B, Boccia R, Vescio RA, Crowley J, Chen H, Berenson JR. Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival. Br J Haematol. 2012 Sep;158(6):727-38. doi: 10.1111/j.1365-2141.2012.09241.x. Epub 2012 Jul 18.</citation>
    <PMID>22804669</PMID>
  </reference>
  <reference>
    <citation>Tai YT, Li XF, Breitkreutz I, Song W, Neri P, Catley L, Podar K, Hideshima T, Chauhan D, Raje N, Schlossman R, Richardson P, Munshi NC, Anderson KC. Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment. Cancer Res. 2006 Jul 1;66(13):6675-82.</citation>
    <PMID>16818641</PMID>
  </reference>
  <reference>
    <citation>Thompson JA, Motzer RJ, Molina AM, Choueiri TK, Heath EI, Redman BG, Sangha RS, Ernst DS, Pili R, Kim SK, Reyno L, Wiseman A, Trave F, Anand B, Morrison K, Doñate F, Kollmannsberger CK. Phase I Trials of Anti-ENPP3 Antibody-Drug Conjugates in Advanced Refractory Renal Cell Carcinomas. Clin Cancer Res. 2018 Sep 15;24(18):4399-4406. doi: 10.1158/1078-0432.CCR-18-0481. Epub 2018 May 30.</citation>
    <PMID>29848572</PMID>
  </reference>
  <reference>
    <citation>Trudel S, Lendvai N, Popat R, Voorhees PM, Reeves B, Libby EN, Richardson PG, Anderson LD Jr, Sutherland HJ, Yong K, Hoos A, Gorczyca MM, Lahiri S, He Z, Austin DJ, Opalinska JB, Cohen AD. Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial. Lancet Oncol. 2018 Dec;19(12):1641-1653. doi: 10.1016/S1470-2045(18)30576-X. Epub 2018 Nov 12.</citation>
    <PMID>30442502</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>January 13, 2021</study_first_submitted>
  <study_first_submitted_qc>May 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 21, 2021</study_first_posted>
  <last_update_submitted>October 8, 2021</last_update_submitted>
  <last_update_submitted_qc>October 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Maryland, Baltimore</investigator_affiliation>
    <investigator_full_name>Ashraf Badros</investigator_full_name>
    <investigator_title>Director of Multiple Myeloma Service</investigator_title>
  </responsible_party>
  <keyword>Belantamab mafodotin</keyword>
  <keyword>Relapsed/Refractory Multiple Myeloma</keyword>
  <keyword>Maximum tolerated doses</keyword>
  <keyword>Overall response rate</keyword>
  <keyword>Overall survival</keyword>
  <keyword>Dose limiting toxicities</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

